# Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)

> **NCT05816720** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 31 (actual)

## Conditions studied

- Neuroendocrine Tumor

## Interventions

- **DRUG:** Lutetium-177 DOTATATE

## Key facts

- **NCT ID:** NCT05816720
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-01
- **Primary completion:** 2022-01-31
- **Final completion:** 2022-01-31
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05816720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05816720, "Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05816720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*